In a phase 1b study of Dato-DXd plus osimertinib in EGFR-mutant NSCLC, the combination showed promising tolerability and antitumor activity, reinforcing the importance of dose optimization and early safety monitoring when integrating ADCs with existing standards of care.33 This evidence concerns the gene EGFR and non-small cell lung carcinoma.